February 20, 2026
Colombia’s regulated medical market entered a new phase in late 2025: the country formally recognized dried flower as a finished product for medical (and veterinary) use, enabling dispensing through licensed pharmacies and drugstores under a physician prescription. This is a meaningful expansion beyond extracts and oils—and it has immediate implications for cannabis compliance, pharmacy SOPs, quality systems, labeling, stability strategy, and export positioning.
This post breaks down what changed, what pharmacies and operators should start preparing now, and how the shift may reshape Colombia’s export mix—especially for EU‑GMP-aligned supply chains.
Focus keyword: Colombia pharmacies cannabis flower 2025 decree
On October 27, 2025, Colombia issued Decree 1138 of 2025, modifying the medical framework housed within the health sector’s unified regulatory decree (Decreto 780 de 2016) as previously substituted by Decree 811 of 2021. The headline change: flower is explicitly recognized as a finished product for medical purposes, allowing it to be commercialized domestically through pharmacies/droguerías and certain veterinary establishments—subject to the applicable control and sanitary oversight.
Key official references:
This reform also resolves a long-standing inconsistency: Colombia had already opened pathways for export of dried flower under Decree 811 of 2021, but domestic commercialization of flower was constrained by regulatory ambiguity.
Multiple public summaries of the decree point to a critical implementation detail: within five (5) months of the relevant article’s entry into force, the government is expected to issue supporting regulation and guidance—particularly for commercialization support and operationalization.
Industry and compliance teams should treat late 2025 through early/mid‑2026 as a build period for:
Colombia’s medical framework is multi‑agency by design, and Decree 1138 reinforces that reality:
Practical takeaway: even if your business “only” grows, manufactures, distributes, or dispenses, your compliance program must anticipate interoperability across these authorities.
Useful official starting points:
Dispensing dried flower through pharmacies shifts the compliance center of gravity from “manufacturing only” to “retail healthcare operations under controlled-substance rules.” Pharmacies should prepare SOPs that combine:
Below are SOP elements that compliance teams should draft, validate, and train against.
At receiving, pharmacies should confirm:
Dried flower introduces risks that are different from oils:
SOP essentials:
Because the model is prescription-driven, pharmacies should implement:
For controlled products, regulators typically expect auditable movement records. Pharmacies should implement:
Foundational pharmacy-service framework:
One of the biggest operational differences between flower and oils is the label. Oils often have standardized concentrations (e.g., mg/mL) and dosing devices. Flower introduces variability and requires tighter batch communication.
While your exact label content must follow what is approved/required for the product’s regulatory pathway, compliance teams should plan for labels that can support:
At a minimum, expect to operationalize labels containing:
INVIMA’s general position on registration/controls for regulated products underscores the need for proper sanitary authorization and compliant labeling through the relevant pathway:
Flower labels must handle additional realities:
Even if Colombia’s domestic rules do not require full pharmaceutical serialization for flower, companies targeting EU/UK channels should consider:
This is less about marketing and more about defensible chain-of-custody in audits and import licensing reviews.
Dried flower behaves like a botanical drug substance/product with potency and quality attributes that can change with:
For EU-facing quality expectations, stability strategies commonly align with ICH principles and herbal medicinal product guidance. A practical industry reference point highlights that stability programs for flower often include (at minimum):
See: “Stability testing for medical Cannabis – What needs to be considered” (GMP Journal): https://www.gmp-journal.com/current-articles/details/stability-testing-for-medical-cannabis-what-needs-to-be-considered.html
Pack-size choices affect both safety and quality:
If multi-dose containers are used, companies should consider in-use stability justification and counseling language that reflects real-world handling.
For dried flower, packaging is part of the stability strategy:
If you’re designing for export, you also need:
Recognizing flower as a finished product pushes operators toward a more pharmaceutical posture:
In the EU context, importers and regulators frequently expect EU‑GMP (or equivalent recognition) for the relevant manufacturing steps, along with a robust QMS and auditable batch documentation.
Colombian operators pursuing EU market share should ensure they can supply:
For broader context on EU expectations around medicinal flower as a regulated product, see:
Historically, many exporters focused on oils/extracts because they are easier to standardize and dose. Domestic pharmacy dispensing of flower changes the commercial calculus.
As pharmacies begin dispensing flower under prescription, domestic demand may:
Exporting finished flower typically requires tighter alignment across:
Key export workflow references:
Even when not explicitly labeled as “GDP,” importers often expect distribution practices consistent with pharmaceutical norms:
Domestic pharmacy distribution can help Colombia demonstrate maturity in regulated dispensary rollout—a narrative that matters for international buyers assessing reliability.
Europe remains a high‑value destination for medically regulated products, but it is document-heavy.
For UK market context on controlled drug licensing expectations:
For Germany, requirements can vary by interpretation across states and product classification, but the direction of travel remains quality- and permit-driven:
As Colombia operationalizes Decree 1138, compliance teams should actively monitor:
On vigilance: INVIMA has formal frameworks for adverse event reporting and pharmacovigilance obligations (not product-specific to flower, but relevant as patient access expands):
This article is for informational purposes only and does not constitute legal advice. Regulations change, and implementation guidance may add or alter operational requirements.
If your team is updating SOPs, labeling, stability plans, or export documentation in response to Colombia’s 2025 changes, use https://cannabisregulations.ai/ to track regulatory updates, build compliance checklists, and pressure-test your licensing and quality documentation before inspections or buyer audits.
Colombia’s regulated medical market entered a new phase in late 2025: the country formally recognized dried flower as a finished product for medical (and veterinary) use, enabling dispensing through licensed pharmacies and drugstores under a physician prescription. This is a meaningful expansion beyond extracts and oils—and it has immediate implications for cannabis compliance, pharmacy SOPs, quality systems, labeling, stability strategy, and export positioning.
This post breaks down what changed, what pharmacies and operators should start preparing now, and how the shift may reshape Colombia’s export mix—especially for EU‑GMP-aligned supply chains.
Focus keyword: Colombia pharmacies cannabis flower 2025 decree
On October 27, 2025, Colombia issued Decree 1138 of 2025, modifying the medical framework housed within the health sector’s unified regulatory decree (Decreto 780 de 2016) as previously substituted by Decree 811 of 2021. The headline change: flower is explicitly recognized as a finished product for medical purposes, allowing it to be commercialized domestically through pharmacies/droguerías and certain veterinary establishments—subject to the applicable control and sanitary oversight.
Key official references:
This reform also resolves a long-standing inconsistency: Colombia had already opened pathways for export of dried flower under Decree 811 of 2021, but domestic commercialization of flower was constrained by regulatory ambiguity.
Multiple public summaries of the decree point to a critical implementation detail: within five (5) months of the relevant article’s entry into force, the government is expected to issue supporting regulation and guidance—particularly for commercialization support and operationalization.
Industry and compliance teams should treat late 2025 through early/mid‑2026 as a build period for:
Colombia’s medical framework is multi‑agency by design, and Decree 1138 reinforces that reality:
Practical takeaway: even if your business “only” grows, manufactures, distributes, or dispenses, your compliance program must anticipate interoperability across these authorities.
Useful official starting points:
Dispensing dried flower through pharmacies shifts the compliance center of gravity from “manufacturing only” to “retail healthcare operations under controlled-substance rules.” Pharmacies should prepare SOPs that combine:
Below are SOP elements that compliance teams should draft, validate, and train against.
At receiving, pharmacies should confirm:
Dried flower introduces risks that are different from oils:
SOP essentials:
Because the model is prescription-driven, pharmacies should implement:
For controlled products, regulators typically expect auditable movement records. Pharmacies should implement:
Foundational pharmacy-service framework:
One of the biggest operational differences between flower and oils is the label. Oils often have standardized concentrations (e.g., mg/mL) and dosing devices. Flower introduces variability and requires tighter batch communication.
While your exact label content must follow what is approved/required for the product’s regulatory pathway, compliance teams should plan for labels that can support:
At a minimum, expect to operationalize labels containing:
INVIMA’s general position on registration/controls for regulated products underscores the need for proper sanitary authorization and compliant labeling through the relevant pathway:
Flower labels must handle additional realities:
Even if Colombia’s domestic rules do not require full pharmaceutical serialization for flower, companies targeting EU/UK channels should consider:
This is less about marketing and more about defensible chain-of-custody in audits and import licensing reviews.
Dried flower behaves like a botanical drug substance/product with potency and quality attributes that can change with:
For EU-facing quality expectations, stability strategies commonly align with ICH principles and herbal medicinal product guidance. A practical industry reference point highlights that stability programs for flower often include (at minimum):
See: “Stability testing for medical Cannabis – What needs to be considered” (GMP Journal): https://www.gmp-journal.com/current-articles/details/stability-testing-for-medical-cannabis-what-needs-to-be-considered.html
Pack-size choices affect both safety and quality:
If multi-dose containers are used, companies should consider in-use stability justification and counseling language that reflects real-world handling.
For dried flower, packaging is part of the stability strategy:
If you’re designing for export, you also need:
Recognizing flower as a finished product pushes operators toward a more pharmaceutical posture:
In the EU context, importers and regulators frequently expect EU‑GMP (or equivalent recognition) for the relevant manufacturing steps, along with a robust QMS and auditable batch documentation.
Colombian operators pursuing EU market share should ensure they can supply:
For broader context on EU expectations around medicinal flower as a regulated product, see:
Historically, many exporters focused on oils/extracts because they are easier to standardize and dose. Domestic pharmacy dispensing of flower changes the commercial calculus.
As pharmacies begin dispensing flower under prescription, domestic demand may:
Exporting finished flower typically requires tighter alignment across:
Key export workflow references:
Even when not explicitly labeled as “GDP,” importers often expect distribution practices consistent with pharmaceutical norms:
Domestic pharmacy distribution can help Colombia demonstrate maturity in regulated dispensary rollout—a narrative that matters for international buyers assessing reliability.
Europe remains a high‑value destination for medically regulated products, but it is document-heavy.
For UK market context on controlled drug licensing expectations:
For Germany, requirements can vary by interpretation across states and product classification, but the direction of travel remains quality- and permit-driven:
As Colombia operationalizes Decree 1138, compliance teams should actively monitor:
On vigilance: INVIMA has formal frameworks for adverse event reporting and pharmacovigilance obligations (not product-specific to flower, but relevant as patient access expands):
This article is for informational purposes only and does not constitute legal advice. Regulations change, and implementation guidance may add or alter operational requirements.
If your team is updating SOPs, labeling, stability plans, or export documentation in response to Colombia’s 2025 changes, use https://cannabisregulations.ai/ to track regulatory updates, build compliance checklists, and pressure-test your licensing and quality documentation before inspections or buyer audits.
